Cargando…
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
BACKGROUND: Insulin is the primary treatment for type 1 and some type 2 diabetes but remains costly in the United States, even though it was discovered more than a century ago. High prices can lead to nonadherence and are often sustained by patents and regulatory exclusivities that limit competition...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653475/ https://www.ncbi.nlm.nih.gov/pubmed/37971985 http://dx.doi.org/10.1371/journal.pmed.1004309 |